Kronos Bio nominates development candidate for Sjogren’s Disease
PremiumThe FlyKronos Bio nominates development candidate for Sjogren’s Disease
1M ago
Kronos Bio to present preclinical data from p300 KAT inhibitor program
Premium
The Fly
Kronos Bio to present preclinical data from p300 KAT inhibitor program
1M ago
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium
Premium
The Fly
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium
2M ago
Kronos Bio price target lowered to $2.25 from $2.50 at H.C. Wainwright
PremiumThe FlyKronos Bio price target lowered to $2.25 from $2.50 at H.C. Wainwright
6M ago
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
Premium
Company Announcements
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
8M ago
Kronos Bio reports Q4 EPS (43c), consensus (52c)
Premium
The Fly
Kronos Bio reports Q4 EPS (43c), consensus (52c)
8M ago
Kronos Bio Announces Top-Level Executives’ Departure
PremiumMarket NewsKronos Bio Announces Top-Level Executives’ Departure
10M ago
Kronos Bio Announces Executive Leadership Changes and Severance Deals
Premium
Market News
Kronos Bio Announces Executive Leadership Changes and Severance Deals
10M ago
Kronos implements new leadership structure, eliminates CMO, CSO, COO roles
Premium
The Fly
Kronos implements new leadership structure, eliminates CMO, CSO, COO roles
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100